Agios Pharmaceuticals | AGIO - Selling And Administration Expenses

Stock Price
29.25
Daily Change
0.67 2.34%
Monthly
7.66%
Yearly
-16.95%
Q1 Forecast
28.34

Agios Pharmaceuticals reported $42.97M in Selling and Administration Expenses for its fiscal quarter ending in December of 2025.





Selling And Administration Expenses Change Date
AbbVie USD 3.89B 325M Dec/2025
Agios Pharmaceuticals USD 42.97M 1.7M Dec/2025
Alnylam Pharmaceuticals USD 285.06M 22.47M Dec/2025
Amgen USD 1.94B 237M Dec/2025
Arrowhead Research USD 46.02M 8.84M Dec/2025
Astellas Pharma JPY 221.78B 14.94B Dec/2025
AstraZeneca USD 4.61B 4.46B Dec/2025
Bayer EUR 3.4B 140M Sep/2025
Biogen USD 545.2M 38.6M Sep/2025
BioMarin Pharmaceutical USD 223.42M 8.86M Sep/2025
Bristol-Myers Squibb USD 2.18B 392M Dec/2025
Daiichi Sankyo JPY 228.23B 39.15B Dec/2025
Eli Lilly USD 3.13B 391.3M Dec/2025
Exelixis USD 123.02M 19.9M Dec/2025
Gilead Sciences USD 1.78B 425M Dec/2025
GlaxoSmithKline GBP 2.68B 518M Dec/2025
Incyte USD 390.41M 61.33M Dec/2025
Ionis Pharmaceuticals USD 86.56M 4.04M Sep/2025
Merck USD 2.85B 215M Dec/2025
Moderna USD 308M 40M Dec/2025
Nektar Therapeutics USD -0.18 0.07 Sep/2024
Novartis USD 3.31B 134M Sep/2025
Novartis USD 3.3B 137M Sep/2025
Pfizer USD 4.08B 894M Dec/2025
Puma Biotechnology USD 16.82M 8.15M Sep/2024
Regeneron Pharmaceuticals USD 775M 117.2M Dec/2025
Roche Holding CHF 7.28B 3.99B Dec/2025
Sarepta Therapeutics USD 77.11M 7.22M Sep/2025
Vertex Pharmaceuticals USD 487M 41.9M Dec/2025